In contrast, anti-B7H3 CAR T-cell therapies exhibited a broader range of adverse effects, including Cytokine Release Syndrome (CRS), although there have been no reported cases of CRS-associated fatalities. The gene discussed is CD276; the disease is congenital rubella syndrome.